In the critical disease group, favorable outcomes were still more prevalent among COVID-19 patients with oral medication only and oral medication plus insulin but was not statistically significant (83.3%, 60% vs. 25% for critical, p=0.090) (Figure 4(a)). The gene discussed is INS; the disease is COVID-19.